Hugel Announces Mid- to Long-Term Goals... Toxin Expanded to Over 80 Countries

"Expansion to Over 70 Countries for HA Fillers
and More Than 10 Countries for Cosmetics"

Hugel, a global total medical aesthetic specialist company, announced its major achievements for 2024 and presented its three-year mid- to long-term goals and growth strategies through 2028.

Eva Hwang, CFO of Hugel, is presenting future plans at the '2025 JP Morgan Healthcare Conference.' Hugel

On the 16th (local time), Hugel announced at the 2025 JP Morgan Healthcare Conference held in San Francisco, USA, that it plans to expand its presence to over 80 countries for toxins, over 70 countries for HA fillers, and more than 10 countries for cosmetics by 2028.

Its specific strategies include ▲maintaining domestic market leadership ▲expanding the global market by accelerating entry into emerging markets such as the Middle East and North Africa ▲strengthening profitability ▲and diversifying its portfolio.

Explanations on key regional market strategies followed. In particular, in the United States, where the official launch of toxins is scheduled for the first half of this year, the plan is to actively target the MZ generation customer base by utilizing skin clinic channels.

Additionally, by providing academic content that meets the needs of local medical professionals and implementing reasonable pricing policies, Hugel aims to achieve a 10% market share in the aesthetic toxin market within three years after launch. Both Europe and China plan to achieve a local toxin market share of 20-25% by 2027.

Eva Hwang, Hugel CFO and the presenter at the event, stated, "Hugel will continue to grow in the global market by leveraging its leading position in the Korean market, a balanced portfolio of toxins, fillers, and cosmetics, and differentiated corporate value," adding, "We will establish ourselves not only as a domestic leader but also as a global top-tier company."

This content was produced with the assistance of AI translation services.